U.S., Dec. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07268560) titled 'Real-World Effectiveness of Aztreonam-Avibactam Against MBL-Producing CRE' on Nov. 17.
Brief Summary: Why This Study is Needed Some bacterial infections have become resistant to common antibiotics, making them very difficult to treat. This is a growing and serious health problem. A new combination drug, Aztreonam-Avibactam (we'll call it ATM-AVI), has been developed to fight these tough bacteria.
This new drug was recently approved for use in Europe (April 2024), the United States (February 2025), and China (June 2025). Because it is so new, there is very little information available, especially in China, on how well it works for re...